8-K: TuHURA Biosciences and Kineta, Inc. Announce Non-Binding Letter of Intent for Potential Acquisition of KVA12123

TuHURA Biosciences and Kineta, Inc. have entered into a non-binding letter of intent for TuHURA to potentially acquire Kineta's KVA12123 VISTA inhibiting antibody.

Summary

• Kineta, Inc. and TuHURA Biosciences have signed a non-binding letter of intent for TuHURA to acquire Kineta's KVA12123, a VISTA inhibiting antibody.
• TuHURA paid Kineta $5 million in July 2024 for exclusivity and a right of first offer, and an additional $300,000 in October 2024 to extend the agreement.
• The potential acquisition of KVA12123 would expand TuHURA's pipeline with a Phase 2 ready asset.
• TuHURA is also advancing its IFx-2.0 program, with a Phase 3 trial planned for the first half of 2025 under a Special Protocol Assessment (SPA) agreement with the FDA.
• TuHURA has secured $31 million in financing following its merger with Kintara Therapeutics, expected to fund operations into the second half of 2025.
• TuHURA is also developing other novel technologies, including tumor microenvironment modulators and a systemically administered tumor-targeted mRNA innate immune response agonist.

Sentiment

Score: 7

Explanation: The document is generally positive, highlighting the potential acquisition, clinical trial progress, and financial stability. However, the non-binding nature of the letter of intent and the inherent risks of drug development temper the overall sentiment.

Positives

• The potential acquisition of KVA12123 would add a Phase 2 ready asset to TuHURA's pipeline.
• TuHURA's IFx-2.0 program is advancing with a planned Phase 3 trial under an SPA agreement with the FDA.
• The $31 million financing provides runway into the second half of 2025.
• TuHURA is expanding its pipeline with novel technologies, including tumor microenvironment modulators and a systemically administered tumor-targeted mRNA innate immune response agonist.
• TuHURA has made key management hires to advance development.

Negatives

• The agreement between TuHURA and Kineta is currently a non-binding letter of intent, and the acquisition is not guaranteed.
• The acquisition of KVA12123 is subject to continuing diligence and negotiations.
• The REM-001 program is being considered for licensing opportunities, indicating a potential shift in focus away from this asset.

Risks

• The potential transaction may not be completed or may not be completed on attractive terms.
• The company's cash resources may not be sufficient to fund all operating expenses and capital requirements.
• The success of clinical trials is not guaranteed, and results may not be favorable.
• There are risks associated with the development and commercialization of new therapies.
• The company is subject to risks related to regulatory approvals and market acceptance.

Future Outlook

TuHURA is focused on advancing its pipeline, including the potential acquisition of KVA12123 and the initiation of a Phase 3 trial for IFx-2.0 in the first half of 2025. The company expects its current financing to fund operations into the second half of 2025.

Management Comments

• James Bianco, M.D., President and Chief Executive Officer of TuHURA, stated that they have made significant progress toward accomplishing their 2024 corporate objectives.
• Dr. Bianco also commented that the potential acquisition of KVA12123 would bring a Phase 2 ready candidate with therapeutic synergies to their pipeline.
• Dr. Bianco expressed excitement about strengthening their leadership team with the appointments of Peter ONeill and Michael Krsulich.

Industry Context

This announcement reflects the ongoing trend in the biotech industry of companies seeking to expand their pipelines through acquisitions and strategic partnerships. The focus on novel immunotherapies and overcoming resistance to existing treatments is also a key trend in the oncology space. TuHURA's approach of targeting the tumor microenvironment and using innate immune response agonists aligns with current research and development efforts in the field.

Comparison to Industry Standards

• The development of VISTA inhibitors like KVA12123 is a growing area of interest in immuno-oncology, with companies like Jounce Therapeutics and Immutep also exploring this pathway.
• TuHURA's IFx technology, which uses a bacterial protein to stimulate the immune system, is a unique approach compared to traditional checkpoint inhibitors, but similar to other companies exploring innate immune agonists such as Idera Pharmaceuticals.
• The use of Special Protocol Assessments (SPA) with the FDA is a common strategy for companies seeking accelerated approval for their therapies, similar to other companies in the oncology space.
• The $31 million financing secured by TuHURA is a significant amount for a company of its size, but is comparable to other biotech companies at a similar stage of development.

Management Changes

Stakeholder Impact

• Shareholders of Kineta and TuHURA will be impacted by the potential acquisition, which could affect the value of their holdings.
• Employees of both companies may experience changes in their roles and responsibilities.
• Patients may benefit from the development of new therapies for cancer.
• The potential acquisition could impact the competitive landscape for other companies in the immuno-oncology space.

Next Steps

• TuHURA aims to reach a definitive agreement for the acquisition of KVA12123 in Q4 2024.
• TuHURA plans to initiate the IFx-2.0 Phase 3 trial in the first half of 2025.
• TuHURA intends to complete the potential acquisition of KVA12123 in the first half of 2025.
• TuHURA plans to commence VISTA inhibiting Mab Phase 2 trials in the second half of 2025 (if the Kineta merger transaction is completed).
• TuHURA will conduct in vivo POC studies for the Bi-specific MDSC targeted ADC in the second half of 2025.
• TuHURA will conduct in vivo POC studies for IFx-3.0: CD22+ tumor targeted mRNA in the second half of 2025.

Key Dates

Keywords

TuHURA Biosciences, Kineta, KVA12123, VISTA Inhibitor, IFx-2.0, Immunotherapy, Phase 3 Trial, Merkel Cell Carcinoma, Acquisition, Bi-specific ADC, PDC, MDSC, Oncology